PK model [Regulatives / Guidelines]

posted by PharmCat  – Russia, 2020-09-10 20:12 (620 d 00:06 ago) – Posting: # 21915
Views: 2,414

Hi Helmut!

I can be wrong.

I suppose when we have modified release dosage form there are can be some changes in the PK model. We shold take in to accaunt that dissolution profile of form in GI can have own dynamic. For example: if absorbtion of dissoluted drug is high and dissolution is linear we can have something with "plato" profile. So resulting PK profile can be wery surprising.

Complete thread:

UA Flag
Activity
 Admin contact
22,092 posts in 4,630 threads, 1,567 registered users;
online 10 (0 registered, 10 guests [including 9 identified bots]).
Forum time: Monday 20:19 CEST (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5